PMID- 16167144
OWN - NLM
STAT- MEDLINE
DCOM- 20060613
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 55
IP  - 7
DP  - 2006 Jul
TI  - Surgical influence of pancreatectomy on the function and count of circulating 
      dendritic cells in patients with pancreatic cancer.
PG  - 775-84
AB  - BACKGROUND: Dendritic cells (DCs) are important for an immune surveillance. 
      Myeloid DCs (DC1) are important for an effective antitumor immune system. The 
      function and count of circulating DC1 (cDC1) in hosts with a malignant tumor 
      would be defective. This study focused on analyzing the immunological features of 
      cDC1 in patients with pancreatic cancer during the perioperative period. 
      MATERIALS AND METHODS: Thirty-two pancreatic cancer patients who underwent 
      pancreatectomy and 18 age-matched healthy individuals as controls were enrolled 
      in this study. The perioperative cDC count, the stimulatory capacity of cDC1 
      against allogeneic T cells and TGF-beta1 level in the serum were measured. The 
      cDC count was measured at 12 months after the operation. RESULTS: The 
      preoperative cDC1/cDC2 ratio, cDC1 count, and stimulatory capacity of cDC1 were 
      impaired in patients in comparison to controls (P<0.05). The serum TGF-beta1 
      level was significantly higher in patients than controls (P<0.001). The 
      stimulatory capacity of cDC1 recovered after pancreatectomy (P<0.05). The serum 
      TGF-beta1 level significantly decreased after the operation (P<0.05); however, 
      they were still significantly higher than controls (P<0.05). Although the 
      cDC1/cDC2 ratio and the cDC1 count did not increase after the pancreatectomy, 
      they recovered as the controls' level at 12 months after the pancreatectomy in 
      disease-free patients (P<0.05) and the serum TGF-beta1 level in those patients at 
      12 months after the operation significantly decreased compared with those at the 
      postoperative period (P<0.05). CONCLUSION: Surgical resection of pancreatic 
      cancer could be associated with improved cDC1 function. When a patient remained 
      disease free, the recovery of cDC1 counts was observed approximately 12 months 
      after pancreatectomy. Further strategy will be needed to improve immune function 
      in patients with pancreatic cancer.
FAU - Takahashi, Kanji
AU  - Takahashi K
AD  - Department of Surgery, Kansai Medical University, 10-15, Fumizono, Moriguchi, 
      570-8507, Japan.
FAU - Toyokawa, Hideyoshi
AU  - Toyokawa H
FAU - Takai, Soichiro
AU  - Takai S
FAU - Satoi, Sohei
AU  - Satoi S
FAU - Yanagimoto, Hiroaki
AU  - Yanagimoto H
FAU - Terakawa, Naoyoshi
AU  - Terakawa N
FAU - Araki, Hiroshi
AU  - Araki H
FAU - Kwon, A-Hon
AU  - Kwon AH
FAU - Kamiyama, Yasuo
AU  - Kamiyama Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050916
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Phytohemagglutinins)
RN  - 0 (TGFB1 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Blood Cell Count
MH  - Case-Control Studies
MH  - Dendritic Cells/*immunology
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Lymphocyte Activation/drug effects
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Middle Aged
MH  - *Pancreatectomy
MH  - Pancreatic Neoplasms/blood/immunology/*surgery
MH  - Phytohemagglutinins/pharmacology
MH  - Postoperative Period
MH  - T-Lymphocytes/drug effects/immunology
MH  - Transforming Growth Factor beta/blood
MH  - Transforming Growth Factor beta1
PMC - PMC11029902
EDAT- 2005/09/17 09:00
MHDA- 2006/06/14 09:00
PMCR- 2005/09/16
CRDT- 2005/09/17 09:00
PHST- 2005/05/16 00:00 [received]
PHST- 2005/08/11 00:00 [accepted]
PHST- 2005/09/17 09:00 [pubmed]
PHST- 2006/06/14 09:00 [medline]
PHST- 2005/09/17 09:00 [entrez]
PHST- 2005/09/16 00:00 [pmc-release]
AID - 79 [pii]
AID - 10.1007/s00262-005-0079-5 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2006 Jul;55(7):775-84. doi: 10.1007/s00262-005-0079-5. 
      Epub 2005 Sep 16.